Research
Hormonal
GLP-1 and GIP/GLP-1 agonists improve heart failure with preserved ejection fraction (HFpEF) symptoms and functional capacity in obese patients, independent of diabetes status.
If you have obesity and heart failure with preserved ejection fraction, discuss GLP-1 agonists with your cardiologist. They can significantly improve your heart failure symptoms, exercise capacity, and quality of life.
StrongSupportsVERY_HIGH confidence
The STEP-HFpEF trial... evaluated weekly semaglutide 2.4 mg vs. placebo in 529 patients with HFpEF and obesity... KCCQ-CSS improved by +16.6 vs. +8.7 with placebo... Weight decreased by –13.3% vs. −2.6%.
Why this rating
Based on randomized controlled trials (STEP-HFpEF, STEP-HFpEF DM, SUMMIT) with significant improvements in functional capacity and symptoms.
Source
Pharmacological therapy in the obese patient: is it only a matter of fat loss?
Claudio Borghi et al. · European Heart Journal Supplements · 2026
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →